Jim Simons Stoke Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 19,100 shares of STOK stock, worth $266,445. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,100

Holding current value

$266,445

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$4.12 - $14.17 $78,692 - $270,647	19,100 New	19,100 $258,000
Q2 2023 Aug 11, 2023	SELL	$7.93 - $13.82 $185,562 - $323,388	-23,400 Reduced 35.62%	42,300 $450,000
Q1 2023 May 12, 2023	SELL	$7.65 - $10.38 $297,585 - $403,782	-38,900 Reduced 37.19%	65,700 $547,000
Q4 2022 Feb 13, 2023	SELL	$7.07 - $15.69 $156,954 - $348,318	-22,200 Reduced 17.51%	104,600 $965,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $22.53 $340,376 - $610,563	-27,100 Reduced 17.61%	126,800 $1.63 Million

Q2 2022 Aug 12, 2022	BUY	$10.36 - $23.93 $1.47 Million - $3.39 Million	141,800 Added 1171.9%	153,900 $2.03 Million
Q1 2022 May 13, 2022	BUY	$17.19 - $26.1 $207,999 - $315,810	12,100 New	12,100 $255,000
Q4 2021 Feb 11, 2022	SELL	$18.11 - $30.72 $1.5 Million - $2.54 Million	-82,800 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$23.65 - $34.44 $35,475 - $51,660	1,500 Added 1.85%	82,800 $2.11 Million
Q2 2021 Aug 13, 2021	BUY	$30.53 - $41.09 $888,423 - $1.2 Million	29,100 Added 55.75%	81,300 $2.74 Million
Q1 2021 May 13, 2021	BUY	$36.08 - $69.81 $1.88 Million - $3.64 Million	52,200 New	52,200 $2.03 Million

Others Institutions Holding STOK

# of Institutions

111

Shares Held

50M

Call Options Held

63K

Put Options Held

111K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $550M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account